Clincosm LogoSign in Get a demo

Early Detection of Cognitive Dysfunction in Diabetes

Sponsor
Wuhan General Hospital of Guangzhou Military Command (Other)
Overall Status
Unknown status
CT.gov ID
NCT01830998
Collaborator
(none)
400
Enrollment
3
Locations
35
Duration (Months)
133.3
Patients Per Site
3.8
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The rate of cognitive decline due to ageing is increased 1.5-fold to 2.0-fold in individuals with type 2 diabetes.There are no established specific treatment measures to prevent or ameliorate cognitive impairments in patients with diabetes. we want to detecte early clinical dementia in diabete.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Clinically relevant cognitive decrements in relation to diabetes mainly occur during two crucial periods in life: the period of brain development in childhood, and the period when the brain undergoes neurodegenerative changes associated with ageing.Potential leads for treatment are to optimise glycaemic control and avoid and treat vascular risk factors.we want to detecte early clinical dementia in diabete by MMSE and Olfactory function.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    400 participants
    Observational Model:
    Case-Control
    Time Perspective:
    Prospective
    Official Title:
    Study of Cognitive Dysfunction and Diabetes
    Study Start Date :
    Jan 1, 2012
    Anticipated Primary Completion Date :
    Dec 1, 2014
    Anticipated Study Completion Date :
    Dec 1, 2014

    Arms and Interventions

    Arm Intervention/Treatment
    control,MCI, Olfactory dsfunction

    There are different groups:control,MCI, Olfactory dsfunction.
    control, MCI

    control and MCI group.Glycaemic control
    control and MCI

    treatment and without treatment
    MCI and Olfactory function

    observation between MCI and Olfactory function groups.

    Outcome Measures

    Primary Outcome Measures

    1. MMSE Olfactory function dementia [2 years]

      MMSE,Olfactory function and PET(fMRI) were observed.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    50 Years to 80 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Patients with type 2 diabetes(Age>50 years)
    Exclusion Criteria:
    • with stroke or other complications.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Wuhan general hospital of Guangzhou command Wuhan,chongqing Hubei China 430070
    2 Wuhan general hospital of Guangzhou Command Wuhan Hubei China 430070
    3 tongji Medical University Wuhan Hubei China 430074

    Sponsors and Collaborators

    • Wuhan General Hospital of Guangzhou Military Command

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    zhipeng xu, doctor, Wuhan General Hospital of Guangzhou Military Command
    ClinicalTrials.gov Identifier:
    NCT01830998
    Other Study ID Numbers:
    • 20130401
    First Posted:
    Apr 12, 2013
    Last Update Posted:
    Dec 10, 2014
    Last Verified:
    Dec 1, 2014
    Keywords provided by zhipeng xu, doctor, Wuhan General Hospital of Guangzhou Military Command
    Dementia
    Olfactory
    Additional relevant MeSH terms:
    Dementia
    Cognitive Dysfunction

    Study Results

    No Results Posted as of Dec 10, 2014